Innovative Immunotherapy for the Treatment of Atopic Dermatitis: Focus on the European and Latin American Regulatory Frameworks

AbstractPurpose of ReviewThis review focused on the mechanisms of action, safety profiles, and efficacy of new and promising systemic immunological treatments for AD. In particular, it has been highlighted how new treatments ’ targets participate in the pathogenic mechanisms of AD. The introduction of new pharmacological agents can provide new therapeutic options, but there is the need to evaluate how “narrow-acting” agents like individual interleukin inhibitors will perform under the safety and efficacy profiles compared with “broad-acting” agents like JAK inhibitors. Furthermore, the article aimed to describe and compare the marketing of these medicines in the European and Latin American markets, comparing the access requirements to these innovative treatments for patients affected from atopic dermatit is in both regions.Recent FindingsModerate to severe AD is often refractory to first-line topical treatments, while systemic immunosuppressants have shown efficacy but have significant side effects. The limited availability of basic treatments has led to the development of targeted topical and systemic immunotherapies, including small molecule drugs and biologics, representing a new era of therapeutic innovation. In 2016, the US Food and Drug Administration (FDA) approved a topical phosphodiesterase-4 inhibitor (PDE4i), crisaborole, and in 2017, a monoclonal antibody, dupilumab.SummaryAtopic dermatitis (AD) is a common inflammatory skin disease characterized by itch...
Source: Current Dermatology Reports - Category: Dermatology Source Type: research